Search

Background and purpose: Anti-programmed death-1 (anti-PD-1) adjuvant therapy and targeted therapy have resulted in longer recurrence-free survival (RFS) for malignant melanoma patients in clinical trials. However, the efficacy of adjuvant anti-PD-1 therapy in Chinese melanoma patients has not been previously reported. The purpose of this study was to retrospectively analyze the RFS in Chinese resected stage Ⅲ malignant melanoma patients treated with adjuvant anti-PD-1 therapy and to preliminarily compare it with BRAFV600 inhibitor vemurafenib. Methods: This study retrospectively collected the information of 120 patients with resected stage Ⅲ malignant melanoma from three major cancer centers in China from August 30, 2018 to August 30, 2020. These patients received adjuvant pembrolizumab/toripalimab or vemurafenib. RFS rates were assessed by Kaplan-Meier curves and log-rank tests were used to examined differences. Results: Among the 90 patients with stage Ⅲ malignant melanoma receiving adjuvant anti-PD-1 therapy, the median-RFS (mRFS) was 16 months (95% CI: 14-18 months); the 12-month RFS rate was 69.5% (95% CI: 64.6%-74.4%) and the 24-month RFS rate was 45.8% (95% CI: 40.5%-51.1%). The mRFS for 30 patients who received vemurafenib was 18 months (95% CI: 10-21 months), the 12-month RFS rate was 62.8% (95% CI: 54.0%-71.6%), and the 24-month RFS rate was 32.9% (95% CI: 27.1%-44.7%). In the stratified analysis, firstly, there was no difference in RFS between anti-PD-1 therapy group and vemurafenib group. Secondly, the BRAFV600E mutation status may did not affect the RFS of anti-PD-1 therapy. In addition, in this study, for the patients with BRAFV600E mutation, the RFS showed no difference between these patients received anti-PD-1 therapy or vemurafenib. Finally, although the RFS was better in patients with cutaneous melanoma than in patients with acral and worst in patients of unknown origin, the data for adjuvant therapy in China were still poor. Conclusion: These are the real-world data from adjuvant anti-PD-1 therapy in patients with resected stage Ⅲ cutaneous and acral melanoma patients in China. In our study, adjuvant anti-PD-1 therapy is indistinguishable from vemurafenib indicates more combination therapies are needed to improve outcome in China.

The experiment was to study the effect of replacing soybean meal with different proportions of whole plant fermentated hybrid tree on growth performance, carcass traits, meat quality and nutrient apparent digestibility of finishing pigs. A total of 48 healthy 'Duroc x Landrace x Yorkshire' crossbred finishing pigs with an initial weight of (60.44±2.51) kg were randomly divided into four groups, with three replicates in each group and four pigs in each replicate. The finishing pigs in group A (control group) were fed with basal diet, and the finishing pigs in group B, group C and group D were fed with experimental diet with 3%, 5% and 7% whole fermented hybrid tree instead of soybean meal, respectively. The pre-test lasted for 10 d, and the formal test lasted for 45 d. The results showed that compared with group A, the average daily gain of finishing pigs in group B was increased by 2.78% (P>0.05), the eye muscle area, intramuscular fat content and protein content of finishing pigs in experimental groups were significantly increased (P<0.05). The apparent digestibility of acid detergent fiber, crude fat, neutral detergent fiber, calcium and phosphorus in diets of finishing pigs in group C and group D were significantly increased (P<0.05). The experiment indicates that using 3% whole plant fermented hybrid tree instead of soybean meal has better effect on growth performance, meat quality and apparent digestibility of finishing pigs. [ABSTRACT FROM AUTHOR]